Product Description
Addressing the prevalence of pet behavioral and mental health issues, alongside the scarcity of pet-specific medications (predominantly off-label human drugs) and significant adverse effects, we develop low-side-effect pet-specific neuropharmacological agents (selective alpha-agonists, sedatives) and behavior-modulating nutritional products incorporating L-theanine and alpha-lactalbumin. We complement these with digital therapy combinations—behavioral management APPs and sensors—enhanced by liposomal encapsulation and AI-powered management technologies to improve efficacy and owner convenience.
